The historical rank and industry rank for ADMA Biologics's Gross Margin % or its related term are showing as below:
ADMA'
s Gross Margin % Range Over the Past 10 Years
Min: -148.42 Med: 12.17 Max: 40.33
Current: 39.39
During the past 13 years, the highestGross Margin % of ADMA Biologics was 40.33%. The lowest was -148.42%. And the median was 12.17%.
ADMA's Gross Margin % is ranked worse than 71.06% of 743
companies
in the Biotechnology industry
Industry Median: 59.33
vs ADMA: 39.39
ADMA Biologics had a gross margin of 47.77% for the quarter that ended in Mar. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for ADMA Biologics was 0.00% per year.
ADMA Biologics Gross Margin % Historical Data
The historical data trend for ADMA Biologics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ADMA Biologics's Gross Margin %
For the Biotechnology subindustry, ADMA Biologics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ADMA Biologics had a gross margin of 47.77% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ADMA Biologics Gross Margin % Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 